This has shown a response rate in refractory patient populations.6 It does have the cytokine release syndrome, but it’s only on the first cycle. We do have an antibody-drug conjugate. About 50% of people express the protein so we need either an old or new biopsy. I think there’s ...
VICUNA: I have not used polatuzumab-BR, but I would [reduce the] dose to manage cytopenias and maybe hold [the patient off the treatment] cycle an extra week—so every 21 days, give them an extra week off to recover. To manage peripheral neuropathy, I may hold [the patient ...
The standard intravenous (IV) dosing of topotecan is 1.5 mg/m2 daily on days 1–5 of a 21-day cycle [39]. A less burdensome schedule of a higher weekly dose of topotecan (6 mg/m2 IV for 6 weeks) in 38 patients with relapsed SCLC yielded no responses in those with refractory ...
Recently, the combination of PARP inhibitor olaparib with the alkylating agent temozolomide was tested in JN-DSRCT-1 cells in vitro and in vivo and the results indicates that the combination has synergistic effects upon cell viability, inducing cell cycle arrest which progress to apoptosis induction,...